Rapid Micro Biosystems, Inc. (Nasdaq: RPID) has entered into a five-year global distribution and collaboration agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma. The partnership, announced on February 27, 2025, significantly extends the commercial reach of Rapid Micro's Growth Direct system through expanded global sales channels.
Under the terms of the agreement, MilliporeSigma receives global co-exclusive rights to sell Growth Direct systems and related consumables to customers across pharmaceutical, medical device, personal care, cosmetics, and food and beverage industries worldwide. Rapid Micro will maintain its existing direct sales team and distribution channels, while retaining responsibility for installation, validation, and service of all Growth Direct systems, including those sold by MilliporeSigma.
The initial five-year term includes a commitment from MilliporeSigma to purchase a minimum number of Growth Direct systems during each of the first two years, though specific quantities were not disclosed.
Strategic Benefits and Collaboration Opportunities
The agreement extends beyond distribution to enable collaboration on product and supply chain costs. Both companies intend to explore cost savings by leveraging MilliporeSigma's product offerings, manufacturing capabilities, and scale to accelerate Rapid Micro's strategic priority of expanding gross margins.
Additional collaboration opportunities include services and joint technology development efforts to enhance existing offerings and introduce new products.
Robert Spignesi, President and CEO of Rapid Micro Biosystems, described the agreement as "a transformative opportunity" for the company.
"MilliporeSigma's global scale, top-tier brand and industry leadership, coupled with Rapid Micro's market-leading Growth Direct system, consumables and services, will significantly expand our commercial reach and depth," said Spignesi. "We are confident this collaboration will enhance value to customers worldwide, while meaningfully advancing our priorities of accelerating Growth Direct System placements, improving gross margins and driving innovation."
Growth Direct System: Modernizing Microbial Quality Control
The Growth Direct system is positioned as the only fully automated, non-destructive growth-based platform for microbial quality control (MQC) testing. The system offers pharmaceutical manufacturers faster time to results, improved data integrity, and enhanced accuracy compared to traditional methods.
By automating and modernizing the manual MQC testing workflows used in complex pharmaceutical manufacturing operations, the Growth Direct system effectively brings quality control capabilities directly to the manufacturing floor. This approach delivers faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision-making.
These advantages are particularly critical for manufacturers of biologics, vaccines, cell and gene therapies, and sterile injectables, where microbial contamination risks must be carefully managed.
Company Background
Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with U.S. manufacturing facilities in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands. The company specializes in providing mission-critical automation solutions that facilitate efficient manufacturing and fast, safe release of healthcare products.
The collaboration with MilliporeSigma represents a significant strategic development for Rapid Micro Biosystems as it seeks to expand its market presence and enhance its technological capabilities in the pharmaceutical manufacturing quality control space.
